Can bone loss in rheumatoid arthritis be prevented?

Area of Science:

• Osteoimmunology
• Rheumatology
• Bone Biology

Background:

• Rheumatoid arthritis (RA) is a systemic inflammatory disease causing joint damage and osteoporosis.
• RA patients have a doubled risk of vertebral and nonvertebral fractures.
• Inflammation, immobility, and glucocorticoids exacerbate fracture risk in RA.

Purpose of the Study:

• To explore the link between immune system pathways and bone loss in RA.
• To investigate the role of the RANKL/OPG pathway in RA-associated bone disease.
• To assess the impact of modern RA treatments on bone health.

Main Methods:

• Review of current literature on osteoimmunology and RA.
• Analysis of the RANKL/OPG pathway's role in inflammation-induced bone loss.
• Evaluation of bone mineral density in RA patients achieving clinical remission.

Main Results:

• Shared pathways exist between local/generalized bone loss and immune system activity.
• The RANKL/OPG pathway is upregulated by inflammation in RA.
• Clinical remission in RA patients is associated with absent or minimal local and generalized bone loss.

Conclusions:

• Modern RA treatments targeting inflammation can preserve bone health.
• Achieving clinical remission is crucial for preventing bone erosions and osteoporosis in RA.
• Osteoimmunology provides insights into managing bone complications in inflammatory diseases.